Lars Hanker

8PUBLICATIONS
78CO-AUTHORS
Tissue engineeringCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 23, 2026
Establishment of a cell line-based 3D co-culture model of the endometrium for studying endometrial receptivity.

|Oct 25, 2024
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.

Janice S Kwon, Helen McTaggart-Cowan, Sarah E Ferguson

|Oct 24, 2024
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

Jonathan Krell, Danielle Shaw, John McGrane

|Jan 11, 2023
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).

Eva Roser, Philipp Harter, Dario Zocholl

|Nov 04, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen

|Aug 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.

Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer

Pageof 2

Frequent Collaborators

3 joint publications

Florian Heitz

3 joint publications

Tjoung-Won Park-Simon

2 joint publications

Jacobus Pfisterer

2 joint publications

Stefan Kommoss